<DOC>
	<DOCNO>NCT01025635</DOCNO>
	<brief_summary>This study investigate safety efficacy new formulation exist medication treatment papulopustular rosacea . The study test active ingredient plus foam foam alone .</brief_summary>
	<brief_title>Safety Efficacy Azelaic Acid Foam , 15 % Papulopustular Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Azelaic acid</mesh_term>
	<criteria>Signed write informed consent Diagnosis papulopustular rosacea ( IGA score moderate severe ) minimum 12 maximum 50 inflammatory lesion ( papule and/or pustule ) persistent erythema without telangiectasia Free clinically significant disease could interfere study Willingness follow study procedure Male female patient least 18 year age Subjects know nonresponders azelaic acid Presence dermatosis might interfere rosacea diagnosis evaluation treatment result Ocular rosacea , phymatous rosacea Any condition therapy opinion investigator may pose risk patient interfere evaluation study Facial laser surgery 6 week prior study Topical systemic use prescription nonprescription medication treat rosacea Use agent investigational drug treat rosacea study Expected use change dose 90 day prior study betablockers , vasodilator , NSAIDs , hormonal treatment drug cause acneiform eruption Known hypersensitivity ingredient investigational product formulation Alcohol drug abuse Incapability give fully inform consent Subject dependent person , i.e. , relative/family member investigator and/or member investigator 's staff Participation another clinical research study within last 4 week randomization study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>rosacea</keyword>
	<keyword>papulopustular</keyword>
	<keyword>azelaic acid</keyword>
	<keyword>foam</keyword>
</DOC>